Rabbit polyclonal to Axl - C-terminal
Synthetic peptide corresponding to Human Axl aa 863-894 (C terminal) conjugated to keyhole limpet haemocyanin.
SKBR3 cell lysate. Human breast carcinoma tissue.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.09% Sodium Azide
Concentration information loading...
Protein G purified
ab72069 is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Abpromise guarantee covers the use of
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/1000. Detects a band of approximately 98 kDa (predicted molecular weight: 98 kDa).
May function as a signal transducer between specific cell types of mesodermal origin. In case of filovirus infection, seems to function as a cell entry factor.
Highly expressed in metastatic colon tumors. Expressed in primary colon tumors. Weakly expressed in normal colon tissue.
Belongs to the protein kinase superfamily. Tyr protein kinase family. AXL/UFO subfamily.
Contains 2 fibronectin type-III domains. Contains 2 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain.
Information by UniProt
Adhesion related kinase antibody
Western blot - Anti-Axl antibody (ab72069)
Anti-Axl antibody - C-terminal (ab72069) at 1/100 dilution + SKBR3 cell lysate at 12.5 µg
Secondary HRP-anti-rabbit Predicted band size: 98 kDa Observed band size: 98 kDa Additional bands at: 25 kDa, 37 kDa, 50 kDa. We are unsure as to the identity of these extra bands.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Axl antibody (ab72069)
ab72069 at 1/50 dilution, staining Axl in human breast carcinoma by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue, followed by peroxidase-conjugated secondary antibody and DAB staining.
This product has been referenced in:
et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat 155:235-51 (2016).
Read more (PubMed: 26759246) »
et al. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma. Oncotarget 7:36956-36970 (2016).
Read more (PubMed: 27172793) »
See all 4 Publications
for this product
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"